Cure8 research brief
PG is a serious skin complication that can occur with UC. This report suggests guselkumab—an IL‑23 blocker used in IBD and dermatology—helped resolve PG in one patient without loss of UC remission, which could be relevant when choosing therapies for patients with both conditions.
Adult patients with ulcerative colitis who develop pyoderma gangrenosum or other inflammatory skin manifestations; gastroenterologists and dermatologists managing extraintestinal IBD complications; researchers studying IL‑23–driven disease.
This is a single case report published as an abstract-level entry. The authors note overlap in IL‑23–driven inflammation between PG and UC and report that guselkumab contributed to treating PG while the patient’s UC remained in clinical remission.
Because this is one case report, it cannot establish how often guselkumab will help other patients with both UC and PG, nor can it define safety or comparative effectiveness. Clinicians and patients may consider this as a piece of emerging evidence that supports further study or specialist discussion when managing difficult extraintestinal skin disease.
If you are considering treatment changes, discuss with your gastroenterologist and dermatologist; they can interpret case reports in the context of your history, prior therapies, and available guidelines.
This entry is abstract-level and reports a single case. Case reports can suggest hypotheses but do not replace controlled studies. Guselkumab is an IL‑23 inhibitor; related biologics (for example, ustekinumab targets IL‑12/23) are also used across IBD and dermatology, but individual treatment choices require specialist guidance.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A new IL-17A drug (vunakizumab) is reported to have triggered severe ulcerative colitis in one patient, suggesting clinicians and patients starting IL-17A inhibitors should watch for early gastrointestinal symptoms.
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.
